AIBT 8-K
Aibotics, Inc. (AIBT)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 20, 2021
20/20 GLOBAL, INC. |
(Exact name of registrant as specified in its charter) |
Nevada |
| 000-56022 |
| 87-0645794 |
(State or other jurisdiction of |
| (Commission File Number) |
| (IRS Employer |
|
|
|
18851 NE 29th Avenue, Suite 700, Aventura, FL |
| 33180 |
(Address of principal executive offices) |
| (Zip code) |
|
|
|
Registrant’s telephone number, including area code: |
| Phone: 954-233-3511 |
n/a |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
None | None | None |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter). Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
EXPLANATORY NOTE
The information in this report, including the exhibit, is being furnished pursuant to Item 7.01 and Item 9.01 of Form 8-K and General Instruction B.2 thereunder. The information will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor will it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
ITEM 7.01—REGULATION FD DISCLOSURE
On January 20, 2021, a press release was issued respecting 20/20 Global, Inc., and its wholly owned subsidiary, Mycotopia Therapies Inc., a copy of which is attached as Exhibit 99.01.
ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS
The following is filed as an exhibit to this report:
Exhibit Number |
|
Title of Document |
|
Location |
|
|
|
|
|
Item 99 |
| Miscellaneous |
|
|
|
| This filing. |
_______________
*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| 20/20 GLOBAL, INC. | |
|
| |
|
| |
Dated: January 21, 2021 | By: | /s/ Benjamin Kaplan |
|
| Benjamin Kaplan, President |
2
Exhibit 99.01
Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector
Company intends to focus on opportunities in the psychedelic space in the Caribbean and distribute Global 20/20 shares at a later date.
MIAMI, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics, announced today the Company has closed the transaction to sell 100% of its Mycotopia Therapy subsidiary to 20/20 Global Inc. (OTC Pink: TWGL). As a result of the transaction closing, Ehave controls approximately 75.77% of the outstanding shares of 20/20 Global. 20/20 Global Inc. plans to file with FINRA to change the name of the company to Mycotopia Therapy. Ehave, Inc. and 20/20 Global will file applicable 8k and 6k filings for the transaction with the SEC and SEDAR.
Ehave Chairman and CEO Ben Kaplan will serve as Chairman and CEO of both Ehave and 20/20 Global. All payments have been made and stock certificates transferred to complete the transaction. In the future, Ehave management intends to present a plan to the Board to provide its shareholders an opportunity to participate in the transaction. Details of the distribution of shares will be provided at a later date when details are available. The Board of Directors of 20/20 Global has stepped down and Ben Kaplan has been named CEO of Global 20/20, as well as Ehave, Inc. In addition to Mr. Kaplan, Mark Croskery has been appointed to the Board of Directors of 20/20 Global. In addition to his responsibilities to the Board of 20/20 Global, Mr. Croskery serves as Chairman and CEO of Croskery Capital Limited in Kingston, Jamaica.
The transaction has been well received in Jamaica and was the subject of an article in the Jamaica Gleaner, a leading Jamaican newspaper that has been published since 1834. The article titled “Ehave Magic Mushroom Company to Enter Jamaica - Taps Croskery as Director of Subsidiary, Kaya As Wellness Adviser And Partner” can be found at http://jamaica-gleaner.com/article/business/20210115/ehave-magic-mushroom-company-enter-jamaica-taps-croskery-director.
20/20 Global and Mycotopia Therapies will be a pure play on the psychedelic space and own 10% of PsyTech, which produces of the psychedelic professional conferences regarding the science of psychedelics and related business opportunities company along with psychedelic tour and travel related businesses. Ehave will continue develop Ketadash, the Ehave Dashboard, its MegaTeam video game applications for children with ADHD, the safety and security of Electronic Health Records (EHRs), improving mental health, and combatting mental illness.
Ehave CEO Ben Kaplan said “We look forward to developing Mycotopia’s business plan as a stand-alone public company. Our goal is to expand the presence of both Ehave and 20/20 Global as separate ecosystems in the psychedelic sector and continue to develop new opportunities.” Mr. Kaplan continued, “We also plan to distribute some of the 20/20 Global shares held by Ehave to its shareholders. We are considering several options and will provide more information once we have ascertained the most beneficial method of distribution for our shareholders.”
Additional Ehave Inc. Information
We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.
The company posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.
Please follow Ehave on Twitter @Ehaveinc1
Exhibit 99.01
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.
About Mycotopia Therapy
Mycotopia Therapy focuses on helping you heal and reclaim your life. Your journey of healing is an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. Additional information on Mycotopia Therapy can be found on the Company’s website at: https://www.mycotopiatherapies.com.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.
Contact for Ehave Inc. and 20/20 Global
Media Inquiries: Gabe Rodriguez
Investor Relations:
Email: [email protected]
Phone: (623) 261-9046